- Home
- IONS vs DINO Comparison
IONS vs DINO Comparison
Compare IONS & DINO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IONS | DINO |
|---|---|---|
| Founded | 1989 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.9B | 12.9B |
| IPO Year | 1996 | 2022 |
Fundamental Metrics
Financial Performance| Metric | IONS | DINO |
|---|---|---|
| Price | $77.82 | $69.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 22 | 15 |
| Target Price | ★ $93.36 | $61.50 |
| AVG Volume (30 Days) | 1.6M | ★ 2.3M |
| Earning Date | 04-29-2026 | 05-01-2026 |
| Dividend Yield | N/A | ★ 3.03% |
| EPS Growth | 21.71 | ★ 238.46 |
| EPS | N/A | ★ 3.56 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $8.01 |
| Revenue Next Year | $77.99 | N/A |
| P/E Ratio | ★ N/A | $20.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $32.00 | $34.42 |
| 52 Week High | $86.74 | $74.73 |
Technical Indicators
Market Signals| Indicator | IONS | DINO |
|---|---|---|
| Relative Strength Index (RSI) | 61.30 | 58.51 |
| Support Level | $75.66 | $47.04 |
| Resistance Level | $82.85 | $74.73 |
| Average True Range (ATR) | 2.45 | 2.59 |
| MACD | 0.28 | 0.31 |
| Stochastic Oscillator | 97.08 | 64.37 |
Price Performance
Historical ComparisonAbout IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
About DINO HF Sinclair Corporation
HF Sinclair is an integrated petroleum refiner that owns and operates seven refineries serving the Rockies, midcontinent, Southwest, and Pacific Northwest, with a total crude oil throughput capacity of 678,000 barrels per day. It can produce 380 million gallons of renewable diesel annually. It holds a marketing business with over 350 distributors and 1,700 wholesale branded sites across 30 states. It also owns and operates 4,500 miles of petroleum product pipelines and terminals principally in the southwestern United States.